EV3 NEUROVASCULAR
Manufacturer adverse-event records for EV3 NEUROVASCULAR come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2006–2016 · thin-book · elevated Death-code · injury-heavy
Death-code intensity
EV3 NEUROVASCULAR carries an elevated Death-code share
Death-coded event_type rows are 277 of 3,790 (7.31% · elevated tercile among 443 manufacturers). Absolute volume is thin-book.
What the Death-code reading shows for EV3 NEUROVASCULAR
The standout signal for EV3 NEUROVASCULAR is Death-code intensity: 7.31% of 3,790 reports (elevated tercile), while absolute volume is thin-book.
As a thinner-book manufacturer, a handful of device families can swing the totals; open the device table rather than reading the company headline alone. Event_type counts are not the same population as Patient Outcomes.
Reports span 14 device types, led in this extract by Injury at 2,080 (54.9% of event_type total). Peak single-year volume reaches 1,017 reports across 10 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (14)
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.